EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical impact of microbial cell-free DNA next-generation sequencing for invasive mold infection—a single-center retrospective observational study

Rebecca Berger iD, Nina Howard, Sarah Grant, Fernando Centeno, Todd Lasco, Mayar Al Mohajer

Therapeutic Advances in Infectious Disease · 2026-04 · 13

DOI: 10.1177/20499361261437009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Infectious Disease, online erschienen am 03.04.2026. Verfasst von Rebecca Berger und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diagnosing invasive mold infections (IMI) is challenging because they typically occur as opportunistic infections in immunocompromised patients who often present with non-specific symptoms. Furthermore, no single test can definitively diagnose IMI, and a proven diagnosis often requires invasive sampling. This sampling can be unsafe and difficult to perform, especially in the immunocompromised population most at risk for these infections.

Objectives

The objective of this study is to assess the clinical utility of plasma microbial cell-free DNA next-generation sequencing (mcfDNA-NGS) for diagnosing invasive mold infections in the context of conventional diagnostic methods.

Design

Retrospective observational study at a quaternary care center (2017–2025).

Methods

The charts of 30 patients with mold-positive mcfDNA-NGS (Karius™ Spectrum; Redwood City, CA, USA) were reviewed, with IMI adjudicated per 2020 EORTC/MSGERC criteria. Provider documentation, medication orders, and patient outcomes were used to assess clinician interpretation of mcfDNA-NGS result accuracy (true positive vs false positive) and its impact on diagnostic and therapeutic decision-making. Turnaround time (TAT) and molecules per microliter (MPM) were summarized.

Results

IMI final classifications were proven (6), probable (8), possible (5), and unclassified (11). Overall, 23/30 (77%) results were true positives. Among these 23 patients with true positive results for mold, 5 (22%) received a new clinical adjudication of IMI that had been entirely missed by conventional diagnostic testing. Furthermore, mcfDNA NGS provided species-level pathogen identification in 9 of the 23 (39%) true positive cases where conventional testing detected fungal elements or elevated biomarkers but could not identify the specific organism. Median TAT was 102 h; median MPM 657. MPM did not differ between true and false positives ( p = 0.86). mcfDNA-NGS changed diagnostic classification in 7/30 (23%) and antimicrobial management in 16/30 (53%). Conclusion: mcfDNA-NGS provided noninvasive, actionable information, informing diagnosis and therapy. Future studies should define optimal stewardship and cost-effectiveness.

Schlagwörter

Stichwörter der Autor:innen

aspergillusimmunosuppressedmicrobial cell-free DNAmucoralesnon-invasive diagnostics

Autor:innen und Institutionen

  • School of Medicine, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA.
  • School of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Department of Pathology, Baylor College of Medicine, Houston, TX, USA.
  • Baylor St. Luke's Medical Center, Houston, TX, USA.

ORCID-Profile: Rebecca Berger

Zitieren

APA

Berger, R., Howard, N., Grant, S., Centeno, F., Lasco, T., & Al Mohajer, M. (2026). Clinical impact of microbial cell-free DNA next-generation sequencing for invasive mold infection—a single-center retrospective observational study. Therapeutic Advances in Infectious Disease, 13. https://doi.org/10.1177/20499361261437009

Vancouver

Berger R, Howard N, Grant S, Centeno F, Lasco T, Al Mohajer M. Clinical impact of microbial cell-free DNA next-generation sequencing for invasive mold infection—a single-center retrospective observational study. Therapeutic Advances in Infectious Disease. 2026;13. doi:10.1177/20499361261437009

BibTeX
@article{Berger2026,
  author = {Berger, Rebecca and Howard, Nina and Grant, Sarah and Centeno, Fernando and Lasco, Todd and Al Mohajer, Mayar},
  title = {Clinical impact of microbial cell-free DNA next-generation sequencing for invasive mold infection—a single-center retrospective observational study},
  journal = {Therapeutic Advances in Infectious Disease},
  year = {2026},
  volume = {13},
  doi = {10.1177/20499361261437009}
}
Kostenlos starten →